-
Product Insights
NewLikelihood of Approval Analysis for Leukocyte Disorders (White Blood Cell Disorders)
Overview How likely is it that the drugs in Leukocyte Disorders (White Blood Cell Disorders) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leukocyte Disorders (White Blood Cell Disorders) Overview Leukocyte...
-
Sector Analysis
NewNetherlands Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Netherlands Defense Market Report Overview As of 2024, the Netherlands defense budget is worth $22.8 billion. The country’s defense budget experienced a sudden increase in 2024, as the Dutch government adjusted to the reality of war on the European continent. Furthermore, Russia’s invasion of Ukraine has compelled the Netherlands to reinforce its defense posture, as it hopes to deter and defend against further Russian aggression. Against the backdrop of war in Europe, the country’s defense budget will grow at a...
-
Product Insights
Rift Valley Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Rift Valley Fever - Drugs In Development, 2023’, provides an overview of the Rift Valley Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rift Valley Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Equine Encephalitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Equine Encephalitis - Drugs In Development, 2023’, provides an overview of the Equine Encephalitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Eastern Equine Encephalitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Eastern Equine Encephalitis - Drugs In Development, 2023’, provides an overview of the Eastern Equine Encephalitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Western Equine Encephalitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Western Equine Encephalitis - Drugs In Development, 2023’, provides an overview of the Western Equine Encephalitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Western Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Venezuelan Equine Encephalitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Venezuelan Equine Encephalitis - Drugs In Development, 2023’, provides an overview of the Venezuelan Equine Encephalitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venezuelan Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chikungunya Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Chikungunya Fever - Drugs In Development, 2023’, provides an overview of the Chikungunya Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Western Equine Encephalitis Vaccine in Western Equine Encephalitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Western Equine Encephalitis Vaccine in Western Equine Encephalitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Western Equine Encephalitis Vaccine in Western Equine Encephalitis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TSIGSD-218 in Chikungunya Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSIGSD-218 in Chikungunya Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSIGSD-218 in Chikungunya Fever Drug Details: TSI-GSD-2I8 is under development for the...